PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 4, 2026Journal of PACS0 citationsOpen Access

Therapeutic Drug Monitoring in Tuberculosis: What a Pulmonologist Must Know?

RKRohit KumarRGRuchi GirotraSSSagar Sharma

Key Points

  • To examine the role of therapeutic drug monitoring in managing tuberculosis treatment, specifically addressing persistent symptoms.
  • Described a case of a 17-year-old female diagnosed with tuberculosis.
  • Initiated first-line anti-tubercular therapy based on clinical and imaging findings.
  • Monitored treatment adherence and dosing throughout the treatment period.
  • The patient continued to experience symptoms after 8 months of treatment.
  • Repeat imaging showed unresolved mediastinal lymphadenopathy despite adherence to standard therapy.

Abstract

Case sCenarioA 17-year-old immunocompetent female presented with prolonged pyrexia of unknown origin and constitutional symptoms, including fatigue and night sweats, for 1 year.She was initiated on first-line ATT based on clinical features, radiological evidence of mediastinal lymphadenopathy, and cytopathology demonstrating necrotizing granulomatous inflammation on endobronchial ultrasound-guided transbronchial needle aspiration.After 8 months of ATT, she continued to have a persistent fever.Repeat imaging revealed unresolved mediastinal lymphadenopathy.Review of her treatment history confirmed optimal weight-based dosing and adherence to

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kumar et al. (2026) studied this question.

synapsesocial.com/papers/69d0adc2659487ece0fa444bhttps://doi.org/10.5005/jpacs-11047-0026
Ask AI
Helpful
Bookmark
Share
View Full Paper